甲海葱次苷 | 33396-37-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 甲海葱次苷
• 中文别名: 甲基海葱次甙；海葱次甲苷；甲基海葱次苷
• 英文名称: Rambufaside
• 英文别名: Meproscillarin；5-[(3S,8R,9S,10R,13R,14S,17R)-3-[(2R,3R,4S,5R,6S)-3,4-dihydroxy-5-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
• CAS: 33396-37-1
• 化学式: C₃₁H₄₄O₈
• 分子量: 544.686
• InChiKey: RKWPZPDLTYBKCL-RVZGXXANSA-N

物化性质

• 熔点：
  213-217℃
• 比旋光度：
  D20 -94° (CH3OH)
• 沸点：
  538.46°C (rough estimate)
• 密度：
  1.29

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  39
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  、 碘甲烷 在 sodium hydride 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 甲醇 为溶剂， 反应 3.0h， 以32%的产率得到甲海葱次苷
  参考文献：
  名称：

  Modulators of Hypoxia Inducible Factor-1 and Related Uses

  摘要：

  这项发明涉及公式I或II的化合物：以及这些化合物的药用盐和前药，以及使用这些化合物调节局部和全身缺氧事件效应的方法。

  公开号：

  US20090023666A1

文献信息

• OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS
  申请人：The Governors of the University of Alberta

  公开号：US20180186721A1

  公开（公告）日：2018-07-05

  Described herein are methods of oxidative coupling of aryl boron reagents with sp 3 -carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis.

  本文描述了一种利用氧化偶联芳基硼试剂与sp3-碳亲核试剂进行反应的方法，以及通过氧化催化实现马隆酸半酯的环境脱羧芳基化。
• Utilities of olefin derivatives
  申请人：——

  公开号：US20040242615A1

  公开（公告）日：2004-12-02

  Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): 1 in which Ar 1 and Ar 2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ 2 -, —CY 2 ═CZ 2 -, —CY 2 Y 3 —CHZ 2 -, —S—, —O—, or the like; Y 1 , Y 2 , Y 3 , Z 1 and Z 2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z 1 and Z 2 may be independently a linker group that may combine with Ar 2 and Ar 1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate of them; are disclosed.

  提供了一种增强apoAI表达活性的化合物。 公式 (I) 的化合物：1 其中Ar1和Ar2独立的是苯基、萘基或单环或双环芳族杂环族，可被选择性地取代； —X—是—N═CZ2-, —CY2═CZ2-, —CY2Y3—CHZ2-, —S—, —O—或类似物； Y1、Y2、Y3、Z1和Z2独立的是氢、卤素、低级烷基、苯基或类似物； Z1和Z2可以独立的是可以与Ar2和Ar1形成缩合环的连接基团； m是0或1，n是0到2； 它们的前药、药用盐或溶剂化物被公开。
• Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
  申请人：Vascular Biogenics Ltd.

  公开号：US20030225035A1

  公开（公告）日：2003-12-04

  Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.

  提供了新型合成的醚化氧化磷脂和利用这些物质预防和治疗动脉粥样硬化和其他相关疾病，以及炎症性疾病、免疫介导性疾病、自身免疫疾病和增生性疾病的方法。此外，还提供了合成醚化和酯化氧化磷脂的方法，以及利用这些物质预防和治疗动脉粥样硬化和其他相关疾病的方法。
• POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS
  申请人：Northwestern University

  公开号：US20190127306A1

  公开（公告）日：2019-05-02

  Disclosed are new polycyclic carbogenic molecules and their methods of synthesis. The new polycyclic carbogenic molecules may be utilized in anti-cancer therapies. In particular, the polycyclic carbogenic molecules may be formulated as pharmaceutical compositions that comprise the small molecules, which compositions may be administered in methods of treating and/or preventing cell proliferative diseases and disorders such as cancer. The new polycyclic carbogenic molecules may be prepared from vinyl- or allyl-substituted cyclohexenone precursors via preparation of a silyl bis-enol ether intermediate.

  揭示了新的多环碳基分子及其合成方法。这些新的多环碳基分子可以用于抗癌疗法。特别是，这些多环碳基分子可以制成包含小分子的药物组合物，这些组合物可以在治疗和/或预防细胞增殖性疾病和癌症等疾病的方法中使用。这些新的多环碳基分子可以通过从乙烯或烯丙基取代的环己酮前体制备硅烷双烯醚中间体来制备。
• [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
  申请人：NOVARTIS AG

  公开号：WO2021156792A1

  公开（公告）日：2021-08-12

  The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

  本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆水平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体，该配体能够结合到细胞外靶分子（例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体），其中细胞表面受体与受体介导的内吞作用相关联，包括以阿斯利康蛋白受体（ASGPR）介导的溶酶体降解和甘露糖-6-磷酸（M6PR）介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。